RxDoctor Payments Data

Constantinos Bacas, OD

Optometrist · Madison, NJNPI 1063136489

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.3% of the total across 62 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 12 manufacturers, the largest accounting for just 19.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $477, 9.1 times the $52 reported in 2022.

$1,115in general payments, 2019–2025

Across 62 payments — averaging $17.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotissue Holdings Inc.$221
  • AbbVie$190
  • Tarsus Pharmaceuticals, Inc.$119
  • Dompe US, Inc.$104
  • Oyster Point Pharma, Inc.$86
  • Sun Pharmaceutical Industries Inc.$85
  • plus $310 from 6 others

What the payments were for

  • Food & beverage$1,08597%
  • Entertainment$303%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,115 in reported general payments places this provider in the 60th percentile of 1,357 optometrist providers in New Jersey.

See all optometrist providers in New Jersey →

Medicare billing

Part B allowed, 2024
$38,343
Medicare patients
144
Services billed
278

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha14$117
Latanoprost15$110
Timolol Maleate12$77

Paid to pharmacies, not to this prescriber.

Other optometrist in Madison

See the full list for New Jersey →

Where these figures come from

Is this you, or does something look wrong? →